Results 61 to 70 of about 13,763 (191)

Alendronate-Induced Esophagitis: Possible Pathogenic Role of Hypersensitivity to Alendronate

Internal Medicine, 2008
Upper gastrointestinal tract mucosal irritations, such as esophagitis, have been reported as rare adverse events due to a variety of aminobisphosphonates, including alendronate sodium, which have been widely used to treat osteoporosis. Although the pathogenesis of aminobisphosphonate-induced esophageal mucosal irritation has not been clearly understood,
Naniwa, Taio, Maeda, Tomoyo, Mizoshita, Tsutomu, Hayami, Yoshihito, Watanabe, Maiko, Banno, Shogo, Ito, Rei   +6 more
openaire   +3 more sources

Nanoparticle‐Mediated Therapy for Glioma: Advances and Prospects

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Various nanocarriers, including liposomes, dendrimers, exosomes and gold nanoparticles, are designed to penetrate the blood‐brain barrier and deliver chemotherapy, radiotherapy, immunotherapy, gene therapy, phototherapy, magnetic hyperthermia and sonodynamic therapy for glioma.
Wenqian Jiang, Jing Fei, Rangrang Fan, Haifeng Chen, Liangxue Zhou, Gang Guo   +5 more
wiley   +1 more source

The effects of sodium alendronate on socket healing after tooth extraction: a systematic review of animal studies [PDF]

Brazilian Oral Research
The aim of this systematic review was to answer the following question: “Does alendronate, a nitrogen-containing bisphosphonate, improve or impair alveolar socket healing after tooth extraction in animal models”?
Nilo Guliberto Martins CHAVARRY, Pedro Villas Boas ABREU, Eduardo Jorge FERES-FILHO, Daniele Masterson Tavares PEREIRA, Lucianne Cople MAIA, Rafael Scaf De MOLON   +5 more
doaj   +1 more source

Relationship between bisphosphonate use and risks of recurrence and mortality among hormone receptor–positive and triple‐negative breast cancer patients

Cancer, Volume 132, Issue 16, 15 August 2026.
Abstract Background Bisphosphonates (BPs) are routinely used as an adjuvant therapy for breast cancer to reduce the risk of bone recurrences given their anti‐resorptive effects on bones and antitumor characteristics. However, there remains limited evidence regarding their utility across different subtypes. Methods In this population‐based cohort study,
Liuye Huang, Linda S. Cook, Mei‐Tzu C. Tang, David R. Doody, Ulrike Peters, Wei Sun, Jeroen R. Huyghe, Kathleen E. Malone, Christopher I. Li   +8 more
wiley   +1 more source

Mind the gap: Adherence to denosumab dosing and cessation guidelines in Australian residential aged care

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2819-2827, August 2026.
This original research used medication administration data to explore adherence to treatment guidelines for the most common osteoporosis medications in long‐term residential aged care (RAC) in Australia. The paper highlights gaps in adherence to treatment guidelines that must be addressed to improve outcomes of older adults living in RAC.
Marea O'Donnell, Johanna I. Westbrook, Bayzidur Rahman, Isabelle Meulenbroeks, Nasir Wabe, Ian D. Cameron, Mark Morgan, Magdalena Z. Raban   +7 more
wiley   +1 more source

From pill to pain: Alendronate‐induced esophageal injury—A case report and review

JGH Open
Background Alendronate is used to treat Paget's bone disease, glucocorticoid‐induced osteoporosis, and postmenopausal osteoporosis because it suppresses osteoclast activity to stop bone resorption.
Zhen Fan, Hayat Khizar, Jinjiao Lu, Anhua Wang, Tong Xun, Xiao Zhang, Hongfeng Zhao   +6 more
doaj   +1 more source

Effect of alendronate on survival and bone properties in Nothobranchius furzeri: insights from a model of accelerated aging

Experimental Gerontology
Alendronate effectively inhibits osteoclastic bone resorption and is considered as first line treatment of osteoporosis. Additionally, several studies suggest a beneficial effect on mortality that goes beyond life-extending effects attributed to the well-
Maria Butylina, Michael Kothmayer, José Basílio, Katharina Wahl-Figlash, Katharina Gelles, Florian Frommlet, Oliver Pusch, Peter Pietschmann   +7 more
doaj   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 334-344, August 2026.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu, Renn‐Chia Lin, Ing‐Lin Chang, Shau‐Huai Fu, Meng‐Ying Tsai, Shun‐Fa Yang   +5 more
wiley   +1 more source

Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects

Journal of Indian Society of Periodontology, 2010
Background and Objectives: Alendronate, an aminobisphosphonate, is capable of inhibiting periodontitis associated osteoclastic activity and hence is effective in protecting the alveolar bone in periodontitis.
Veena H, Prasad Deepak
doaj  

Effect of early intra ⁃ articular injection of alendronate in reducing subchondral bone loss in rat mandibular condyle after ovariectomy

口腔疾病防治, 2017
Objective To investigate the effects of intra⁃articular injection of alendronate on the mandibular condyle in ovariectomized rats. Methods Sixty female rats were randomly divided into five groups: ovariectomy with vehicle treat⁃ ment alone, early ...
ZHU Song⁃ song
doaj   +1 more source